Ionis Pharmaceuticals IONS Payments to Acquire Debt Securities, Available-for-Sale
Payments to Acquire Debt Securities, Available-for-Sale at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's payments to acquire debt securities, available-for-sale.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's payments to acquire debt securities, available-for-sale?
- Ionis Pharmaceuticals (IONS) reported payments to acquire debt securities, available-for-sale of $192.76M in Q1 2026.
- How has Ionis Pharmaceuticals's payments to acquire debt securities, available-for-sale changed year-over-year?
- Ionis Pharmaceuticals's payments to acquire debt securities, available-for-sale decreased by 38.0% year-over-year, from $311.07M to $192.76M.
- What is the long-term trend for Ionis Pharmaceuticals's payments to acquire debt securities, available-for-sale?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's payments to acquire debt securities, available-for-sale has grown at a 14.3% compound annual growth rate (CAGR), from $1.12B to $1.92B.
- What does payments to acquire debt securities, available-for-sale mean?
- Cash spent on buying investment-grade debt securities.
- How do you interpret payments to acquire debt securities, available-for-sale?
- High outflows indicate active treasury management and deployment of excess cash into short-term investments.
- How does payments to acquire debt securities, available-for-sale compare across companies?
- Common for companies with significant cash balances and conservative treasury policies.